R&D News | pharmaphorum

News

Roche pulls extended use application for kidney cancer drug

Roche has withdrawn an application to the European Medicines Agency (EMA) for an expanded use for its immunotherapy drug, Tecentriq.

News

Merck and Pfizer chalk up another fail for Bavencio

Merck KGaA and Pfizer’s late entrant to the checkpoint inhibitor category has failed a phase III trial in ovarian cancer, denting their hopes of building momentum for the product.

News

Eyeing Novartis deal, Akcea trumpets lipoprotein drug data

Ionis affiliate Akcea Pharma has new data for its antisense drug for elevated lipoprotein levels in patients with cardiovascular disease that it hopes will entice Novartis into a licensing deal.

News

Entresto tops mainstay ACE inhibitor in heart failure trial

Two years ago, Novartis launched a big trials programme for its heart failure drug Entresto in the hope of revving up disappointing initial sales, and one of those trials has just delivered positiv

News

Gilead pushes on with NASH drug after phase 2 success

Gilead Sciences presented promising data on its research into advanced fibrosis caused by non-alcoholic steatohepatitis (NASH), one of several big pharma companies developing drugs for the

News